logo
Plus   Neg
Share
Email

MarineMax Q4 Profit Rises

MarineMax Inc. (HZO) reported that its net income for the fourth-quarter ended September 30, 2018, was $11.5 million or $0.50 per share, compared to net income of $3.9 million, or $0.17 per diluted share in the comparable period last year.

Excluding the impact from the gain in 2018 and the unusual items in 2017, adjusted earnings per share for the quarter ended September 30, 2018 increased 105% to $0.45, compared with adjusted diluted earnings per share for the same period last year.

For the quarter ended September 30, 2018, revenue increased over 23% to $309 million from $251 million for the comparable quarter last year. Same-store sales for the quarter grew 22%, on top of 5% growth for the comparable period last year.

Analysts polled by Thomson Reuters expected the company to report earnings of $0.23 per share and revenues of $273.31 million for the quarter. Analysts' estimates typically exclude special items.

The company currently expects fully taxed earnings per share to be in the range of $1.85 to $1.95 for fiscal 2019. This compared to a non-GAAP adjusted diluted earnings per share of $1.70 in fiscal 2018. Analysts expect annual earnings of $1.68 per share.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
PG&E agreed to pay around $13.5 billion to settle all individual claims related to California wildfires, due to which the electric utility had to file for bankruptcy. With the Bankruptcy Court's approval of the settlement agreement, PG&E hopes to emerge from Chapter 11 by the June 30, 2020 deadline to participate in the State of California's go-forward wildfire fund. Airbnb has introduced few new rules to control parties and nuisances amidst the backlash the service received after the Halloween shooting at an Airbnb rental in a San Francisco. San Francisco-based Airbnb said it is banning "open invite" parties at all of its accommodations. The company is also banning... The U.S. Food and Drug Administration has approved three generic versions of Novartis' Gilenya capsule for treating relapsing forms of multiple sclerosis. "Approving safe and effective generics so patients have more treatment options continues to be a priority for the FDA," said Janet Woodcock, director...
RELATED NEWS
Follow RTT
>